Takeda-6d is a novel dual inhibitor of DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) with anticancer activity. It inhibits wild-type B-RAF, mutant B-RAFV600E, and C-RAF (IC50s = 12, 7, and 1.5 nM, respectively), as well as VEGFR2 (IC50 = 2.8 nM). Takeda-6d (10 mg/kg) reduces tumor volume in an A375 melanoma mouse xenograft model.
纯度：≥98%
CAS：1125632-93-0
